/PRNewswire/ The Board of Directors of Eli Lilly and Company (NYSE:LLY) has elected Mary Lynne Hedley, Ph.D., as a new member, effective May 15, 2022. As a.
The submission to the European Medicines Agency is based on results from the Phase 3 MAGNITUDE study evaluating niraparib in combination with abiraterone acetate plus prednisonefor the treatment of
Rise in awareness of regulatory authorities about environmental welfare and increase in demand for in vitro methods for cancer diagnosis drive the growth of the global in vitro toxicity testing